NEJM January 1, 2025

Multidrug-resistant tuberculosis (MDR-TB) is a growing public health problem.1 Recently, the World Health Organization endorsed new regimens for the treatment of MDR-TB that rely on new and repurposed antibiotic agents (i.e., bedaquiline, pretomanid, and linezolid with or without moxifloxacin [BPaL/M]).2 Much of the global burden of MDR-TB is driven by patient-to-patient transmission of drug-resistant Mycobacterium tuberculosis3 and since BPaL/M is used to treat MDR-TB, resistance to these drugs that is emerging in patients with MDR-TB could spread. On the other hand, experimental...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID
Related Articles:
How Climate-Driven Disasters Could Reshape Health Care Quality Measures
Journalists Discuss Health Care for Incarcerated Children and the Possibility of a Bird Flu Pandemic
What Is HKU5-CoV-2? Scientists Find Bat Virus Similar To COVID-19
Insights into the future of COVID-19 care
Texas Measles Outbreak Nears 100 Cases, Raising Concerns About Undetected Spread

Share This Article